Drug
Cv09050101 Mrna Vaccine 12 G
Cv09050101 Mrna Vaccine 12 G: highest development phase Phase 1, developed by CureVac. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- CureVac
Trials
| Drug | Phase | Indication |
|---|---|---|
| CV09050101 mRNA vaccine (CVGBM) 12 μg NCT05938387 | Phase 1 | Glioblastoma |
Latest
No recent events.
Follow Cv09050101 Mrna Vaccine 12 G on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.